Project objectives
A randomized phase II study of pembrolizumab (MK3475) as maintenance therapy in patients with inoperable stage III non-small cell lung cancer (NSCLC) who have undergone definitive chemoradiation. The purpose of this study is to evaluate whether maintenance treatment with pembrolizumab (24 months) prolongs disease-free survival compared to observation alone in patients with stage III non-small cell lung cancer (NSCLC) who are not eligible for surgical resection and who have achieved a response or stable disease following chemoradiation.
Start and end date
January 2018 - ongoing
Project managers
prof Sara Ramella
Coordinating institution of the project
University of Turin
Funding sources
No profit
